Martyn A. Sharpe, Ph.D.Research Scientist
Methodist Neurological Institute
Department of Neurosurgery
Houston Methodist Hospital
Dr. Sharpe is a chemistry-based biochemist and pharmacologist interested in the role of reactive oxygen and nitrogen species in patho-physiology. He trained in classical biochemistry, with a focus on mitochondrial function after acquiring a strong background in both organic and inorganic chemistry. After post-doctoral training in the United Kingdom, he served as a visiting professor at Michigan State University in East Lansing before joining the Methodist Neurological Institute.
His special research interest is in mitochondrial reactive oxidative/nitrosative species (RO/NS) damage, which has led him into design and synthesis a range of small, superoxide dismutase, catalase and glutathione peroxidase mimetics. To be able to study changes in cells caused by RO/NS, he has developed a number of quantitative assay systems to measure different types of DNA damage. Recently, he and other researchers at Houston Methodist have developed new technologies and drugs to treat glioma. The team recently licensed the rights to our first drug family to a venture capital company.
Education & Training
B.S., 1985, biochemistry, Chelsea College, London, UK
Sharpe, M.A., Marcano, D.C., Berlin, J. M., Widmayer, M.A., Baskin, D.S and Tour, J.M. (2012)
Sharpe, M.A. Livingston, A.D. and Baskin, D.S. (2012)
Sharpe, M.A., Widmayer, M.A and Baskin, D.S. (2010)
Baskin, D.S., Widmayer, M.A and Sharpe, M.A. (2010)
Sharpe, M. A and Ferguson-Miller, S (2008)